BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, Gori S, Del Mastro L. Follow-up of patients with early breast cancer: Is it time to rewrite the story? Critical Reviews in Oncology/Hematology 2014;91:130-41. [DOI: 10.1016/j.critrevonc.2014.03.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Voelkel V, Draeger T, van Mossel S, Siesling S, Koffijberg H. The value of time-dependent risk predictions in a screening context - a comprehensive simulation analysis validated on German cancer registry data. BMC Med Res Methodol 2022;22. [DOI: 10.1186/s12874-022-01718-2] [Reference Citation Analysis]
2 Anoop TM, Joseph P R, Soman S, Chacko S, Mathew M. Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study. World J Clin Oncol 2022; 13(6): 529-539 [DOI: 10.5306/wjco.v13.i6.529] [Reference Citation Analysis]
3 Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A, Ishihara S, Morisaki T, Shibutani M, Tanaka H, Hirakawa K, Ohira M. Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer. BMC Womens Health 2021;21:225. [PMID: 34051785 DOI: 10.1186/s12905-021-01373-7] [Reference Citation Analysis]
4 Davidson T, Shehade N, Nissan E, Sklair-Levy M, Ben-Haim S, Barshack I, Zippel D, Halevy A, Chikman B. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases. Surg Oncol 2021;38:101567. [PMID: 33866190 DOI: 10.1016/j.suronc.2021.101567] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Gerratana L, Davis AA, Polano M, Zhang Q, Shah AN, Lin C, Basile D, Toffoli G, Wehbe F, Puglisi F, Behdad A, Platanias LC, Gradishar WJ, Cristofanilli M. Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. Eur J Cancer 2021;143:147-57. [PMID: 33307492 DOI: 10.1016/j.ejca.2020.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
6 Tyuryumina EY, Neznanov AA, Turumin JL. A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer. Cancers (Basel) 2020;12:E2344. [PMID: 32825078 DOI: 10.3390/cancers12092344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Draeger T, Voelkel V, Groothuis-Oudshoorn CGM, Lavric M, Veltman J, Dassen A, Boersma LJ, Witteveen A, Sonke GS, Koffijberg H, Siesling S. Applying Risk-Based Follow-Up Strategies on the Dutch Breast Cancer Population: Consequences for Care and Costs. Value Health 2020;23:1149-56. [PMID: 32940232 DOI: 10.1016/j.jval.2020.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hing JX, Mok CW, Tan PT, Sudhakar SS, Seah CM, Lee WP, Tan SM. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance. Breast 2020;52:95-101. [PMID: 32485607 DOI: 10.1016/j.breast.2020.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
9 Freitas M, Nouws HP, Keating E, Delerue-matos C. High-performance electrochemical immunomagnetic assay for breast cancer analysis. Sensors and Actuators B: Chemical 2020;308:127667. [DOI: 10.1016/j.snb.2020.127667] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
10 Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, Hirokaga K, Yamaguchi K, Saji S, Iwata H. The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition. Breast Cancer 2020;27:17-24. [PMID: 31734900 DOI: 10.1007/s12282-019-01025-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
11 Voelkel V, Draeger T, Groothuis-Oudshoorn CGM, de Munck L, Hueting T, Gerken M, Klinkhammer-Schalke M, Lavric M, Siesling S. Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. J Cancer Res Clin Oncol 2019;145:1823-33. [PMID: 30927074 DOI: 10.1007/s00432-019-02904-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
12 Schunkert EM, Zhao W, Zänker K. Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option? Biomed Hub 2018;3:1-17. [PMID: 31988964 DOI: 10.1159/000492929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Kozak MM, Jacobson CE, von Eyben R, Walck E, Pollom EL, Telli M, Horst KC. Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy. Clinical Breast Cancer 2018;18:e1077-85. [DOI: 10.1016/j.clbc.2018.04.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mejri N, Benna M, El Benna H, Soumaya L, Afrit M, Zouari B, Boussen H. First site of recurrence after breast cancer adjuvant treatment in the era of multimodality therapy: which imaging for which patient during follow-up? Breast Dis 2018;37:123-32. [PMID: 29171964 DOI: 10.3233/BD-170290] [Reference Citation Analysis]
15 Wait S, Han D, Muthu V, Oliver K, Chrostowski S, Florindi F, de Lorenzo F, Gandouet B, Spurrier G, Ryll B, Wierinck L, Szucs T, Hess R, Rosvall-puplett T, Roediger A, Arora J, Yared W, Hanna S, Steinmann K, Aapro M. Towards sustainable cancer care: Reducing inefficiencies, improving outcomes—A policy report from the All.Can initiative. Journal of Cancer Policy 2017;13:47-64. [DOI: 10.1016/j.jcpo.2017.05.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
16 Piva R, Ticconi F, Ceriani V, Scalorbi F, Fiz F, Capitanio S, Bauckneht M, Cittadini G, Sambuceti G, Morbelli S. Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence. Breast Cancer (Dove Med Press) 2017;9:461-71. [PMID: 28740429 DOI: 10.2147/BCTT.S111098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
17 Bond-Bero S. Filling the Gap for Early-Stage Breast Cancer Follow-Up: An Overview for Primary Care Providers. J Midwifery Womens Health 2016;61:166-76; quiz 284. [PMID: 27037535 DOI: 10.1111/jmwh.12439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Kirshbaum MN, Dent J, Stephenson J, Topping AE, Allinson V, McCoy M, Brayford S. Open access follow-up care for early breast cancer: a randomised controlled quality of life analysis. Eur J Cancer Care (Engl) 2017;26. [PMID: 27717057 DOI: 10.1111/ecc.12577] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
19 Puglisi F, Agostinetto E, Gerratana L, Bozza C, Cancian M, Iannelli E, Ratti G, Cinieri S, Numico G. Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy. Future Oncol 2017;13:233-48. [PMID: 27615389 DOI: 10.2217/fon-2016-0383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
20 Curran J. How effective is mammography in detecting breast cancer recurrence in women after Breast Conservation Therapy (BCT) – A systematic literature review. Radiography 2016;22:252-6. [DOI: 10.1016/j.radi.2016.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Swetter SM. Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma. J Am Acad Dermatol 2016;75:525-7. [PMID: 27317056 DOI: 10.1016/j.jaad.2016.05.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
22 Moschetti I, Cinquini M, Lambertini M, Levaggi A, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2016;:CD001768. [PMID: 27230946 DOI: 10.1002/14651858.CD001768.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
23 Podlipnik S, Carrera C, Sánchez M, Arguis P, Olondo ML, Vilana R, Rull R, Vidal-Sicart S, Vilalta A, Conill C, Malvehy J, Puig S. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol 2016;75:516-24. [PMID: 27183845 DOI: 10.1016/j.jaad.2016.02.1229] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 6.5] [Reference Citation Analysis]
24 Fontanella C, Puglisi F. Translational and clinical research highlights from the 38th San Antonio Breast Cancer Symposium. Future Oncology 2016;12:1005-8. [DOI: 10.2217/fon-2016-0021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Hammon M, Dankerl P, Janka R, Wachter DL, Hartmann A, Schulz-Wendtland R, Uder M, Wenkel E. Fine needle aspiration cytology of lymph nodes in breast cancer follow-up is a feasible alternative to watchful waiting and to histology. BMC Womens Health 2015;15:114. [PMID: 26631071 DOI: 10.1186/s12905-015-0269-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Fontanella C, Fanotto V, Rihawi K, Aprile G, Puglisi F. Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis 2015;32:819-33. [PMID: 26343511 DOI: 10.1007/s10585-015-9743-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
27 Abdel-rahman O, Alorabi M. Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. Expert Review of Anticancer Therapy 2015;15:829-37. [DOI: 10.1586/14737140.2015.1047766] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
28 Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, Puglisi F. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis 2015;32:125-33. [PMID: 25630269 DOI: 10.1007/s10585-015-9697-2] [Cited by in Crossref: 74] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]